Johnson & Johnson (JNJ) vs Moderna, Inc. (MRNA): Which Is the Better Buy in 2026?
As of 2026-09-17, JNJ is fairly valued at $269, with a DCF intrinsic value of $303 and a margin of safety of 11%. MRNA is overvalued at $160, with an intrinsic value of $67 and a margin of safety of -140%. Of the two, JNJ has the wider margin of safety.
Rewards
- ★Johnson & Johnson has maintained ROIC above 15% for 4 consecutive years, indicating a durable competitive advantage.
- ★Gross margin of 68.1% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
- ★Johnson & Johnson scores 90/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.
Risks
- ⚠FCF yield of 2.6% is below 3%, meaning the market is pricing in substantial future growth to justify the current price.
- ⚠Trailing P/E of 31.2x is 56% above the historical average of 20.0x — the stock trades at a premium to its own history.
- ⚠PEG ratio of 2.79 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.
- ⚠ROIC has declined by 67.4 percentage points over the past 4 years, which may signal competitive erosion.
- ⚠Gross margin of -66.0% is low, suggesting a competitive or commodity-like market with limited pricing power.
- ⚠Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.
Key Valuation Metrics
Learn more →Historical Fundamentals
Learn more →Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.
Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.
Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.
$1 Retained Earnings Test
Learn more →> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
Discounted Cash Flow (DCF) Analysis
Learn more →Reverse DCF — Market-Implied Growth
Learn more →What growth rate is the market pricing in at $269?
The market implies +9.8% Owner Earnings growth, above historical trends.
Standard FCF implies a demanding +17.2%, reflecting heavy growth investment.
What growth rate is the market pricing in at $160?
Market pricing in significantly higher growth than history — aggressive.
Economic Moat Score
Learn more →Wide moat with strength across all dimensions. Revenue Predictability is the standout factor.
No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.
Forensic Accounting
Learn more →M-Score Trend
Insufficient data for Beneish M-Score calculation (requires 2+ years).
Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
Ownership Breakdown
Learn more →High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.
Insider Buying Activity
Learn more →Open market purchases · includes direct & indirect ownership · excludes option exercises.
Insider Selling Activity
Learn more →Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.
🎭 Mr. Market's Mood
Learn more →"Market is optimistic — be cautious and ensure you have a margin of safety"
"Market is pricing this stock without strong emotion in either direction"
Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
⚖️ Buffett Signal
Learn more →The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.
The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.
Frequently Asked Questions: JNJ vs MRNA
Is Johnson & Johnson or Moderna, Inc. more undervalued in 2026?▼
Based on our discounted cash flow model, JNJ trades at a 11.0% margin of safety (intrinsic value $303 vs. price $269), compared to MRNA's -140.4% margin of safety (intrinsic $67 vs. $160).
Which stock has a wider economic moat, Johnson & Johnson or Moderna, Inc.?▼
JNJ scores 90/100 (Wide moat), while MRNA scores 17/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.
Is Moderna, Inc. in financial distress?▼
MRNA's Altman Z-Score of 2.5 places it in the Grey zone, signaling elevated bankruptcy risk. JNJ scores 3.5 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.
Which company has better free cash flow, Johnson & Johnson or Moderna, Inc.?▼
Johnson & Johnson (JNJ) generates a 2.6% free cash flow yield, compared to Moderna, Inc.'s 0.5%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.
Which stock has higher return on invested capital, Johnson & Johnson or Moderna, Inc.?▼
JNJ earns 16.9% ROIC versus MRNA's -122.0%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.